Article: Thymosin-α1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleThymosin-α1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase
AuthorsLau, GKK3
Nanji, A3
Hou, J1
Fong, DYT2
Au, WS2
Yuen, ST3
Lin, M2
Kung, HF2
Lam, SK3
KeywordsFamciclovir
HBV
Immune tolerant
Thymosin-α1
Issue Date2002
CitationJournal Of Viral Hepatitis, 2002, v. 9 n. 4, p. 280-287 [How to Cite?]
DOI: http://dx.doi.org/10.1046/j.1365-2893.2002.00361.x
AbstractWe examined whether combination therapy with thymosin-α1 and famciclovir would induce hepatitis B e antigen seroconversion in patients with chronic hepatitis B infection in the immune-tolerant phase without inducing significant hepatic necro-inflammation. We studied 32 hepatitis B e antigen positive patients in the immune-tolerant phase of infection, treated with 26-weeks combination therapy of famciclovir and thymosin-α1 (group 1). Thirty-two patients who received 26-weeks famciclovir monotherapy (group 2) and another 32 patients who received no treatment (group 3), served as controls. Peripheral blood mononuclear cell proliferation and cytokine secretion in response to recombinant HBV core and surface antigen and serial serum HBV-DNA, were assayed. No significant difference in adverse events were observed among the three groups. By week 26, the median reduction in group 1 (0.94 log 10 copies/mL) was greater than group 2 (0.70 log 10 copies/mL, P < 0.001). Five (15.6%) patients in group 1 at 52 weeks (median range 13-78 weeks) and none in group 2 or 3 experienced hepatitis B e antigen seroconversion (P = 0.053). Sustained serological clearance of hepatitis B e antigen was associated with activation of CD4 positive HBV-specific T-cell reactivity and were of T-helper 1. Hence combination therapy with immunomodulatory agents and nucleoside analogues should be explored.
ISSN1352-0504
2011 Impact Factor: 4.088
2011 SCImago Journal Rankings: 0.375
DOIhttp://dx.doi.org/10.1046/j.1365-2893.2002.00361.x
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorLau, GKK
dc.contributor.authorNanji, A
dc.contributor.authorHou, J
dc.contributor.authorFong, DYT
dc.contributor.authorAu, WS
dc.contributor.authorYuen, ST
dc.contributor.authorLin, M
dc.contributor.authorKung, HF
dc.contributor.authorLam, SK
dc.date.accessioned2012-10-08T03:10:46Z
dc.date.available2012-10-08T03:10:46Z
dc.date.issued2002
dc.description.abstractWe examined whether combination therapy with thymosin-α1 and famciclovir would induce hepatitis B e antigen seroconversion in patients with chronic hepatitis B infection in the immune-tolerant phase without inducing significant hepatic necro-inflammation. We studied 32 hepatitis B e antigen positive patients in the immune-tolerant phase of infection, treated with 26-weeks combination therapy of famciclovir and thymosin-α1 (group 1). Thirty-two patients who received 26-weeks famciclovir monotherapy (group 2) and another 32 patients who received no treatment (group 3), served as controls. Peripheral blood mononuclear cell proliferation and cytokine secretion in response to recombinant HBV core and surface antigen and serial serum HBV-DNA, were assayed. No significant difference in adverse events were observed among the three groups. By week 26, the median reduction in group 1 (0.94 log 10 copies/mL) was greater than group 2 (0.70 log 10 copies/mL, P < 0.001). Five (15.6%) patients in group 1 at 52 weeks (median range 13-78 weeks) and none in group 2 or 3 experienced hepatitis B e antigen seroconversion (P = 0.053). Sustained serological clearance of hepatitis B e antigen was associated with activation of CD4 positive HBV-specific T-cell reactivity and were of T-helper 1. Hence combination therapy with immunomodulatory agents and nucleoside analogues should be explored.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationJournal Of Viral Hepatitis, 2002, v. 9 n. 4, p. 280-287 [How to Cite?]
DOI: http://dx.doi.org/10.1046/j.1365-2893.2002.00361.x
dc.identifier.doihttp://dx.doi.org/10.1046/j.1365-2893.2002.00361.x
dc.identifier.epage287
dc.identifier.issn1352-0504
2011 Impact Factor: 4.088
2011 SCImago Journal Rankings: 0.375
dc.identifier.issue4
dc.identifier.scopuseid_2-s2.0-0036633685
dc.identifier.spage280
dc.identifier.urihttp://hdl.handle.net/10722/167738
dc.identifier.volume9
dc.languageeng
dc.publisher.placeUnited Kingdom
dc.relation.ispartofJournal of Viral Hepatitis
dc.relation.referencesReferences in Scopus
dc.subjectFamciclovir
dc.subjectHBV
dc.subjectImmune tolerant
dc.subjectThymosin-α1
dc.titleThymosin-α1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase
dc.typeArticle
Author Affiliations
  1. Nanfang Hospital
  2. The University of Hong Kong
  3. Queen Mary Hospital Hong Kong